Identifying new therapeutics for Huntington's disease

Clinical Neuroscience Research

Volumn 3, Issue 3, 2003, Pages 179-186

  Schilling, Gabriele ^a   Borchelt, David R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Huntingtin; Knoch in mice; Neuropathology; Therapeutic trials; Transgenic mice

Indexed keywords

CREATINE; CYSTAMINE; DICHLOROACETIC ACID; GENE PRODUCT; HUNTINGTIN; LENTIVIRUS VECTOR; MINOCYCLINE; POLYGLUTAMINE; RECOMBINANT PROTEIN; REMACEMIDE; THIOCTIC ACID; UBIDECARENONE; VORINOSTAT;

ANIMAL MODEL; DISEASE COURSE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SCREENING; HUNTINGTON CHOREA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; TRANSGENIC MOUSE; VIRAL GENE THERAPY;

EID: 0141828349     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1566-2772(03)00060-4     Document Type: Article

References (83)

1. Ross C.A. Margolis R.L. Rosenblatt A. Ranen N.G. Becher M.W. Aylward E. Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA) Medicine 76 1997 305-338
2. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971-983
3. La Spada A.R. Wilson E.M. Lubahn D.B. Harding A.E. Fischbeck K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy Nature 352 1991 77-79
4. Orr H.T. Chung M.-Y. Banfi S. et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1 Nat Genet 4 1993 221-226
5. Kawaguchi Y. Okamoto T. Taniwaki M. et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1 Nat Genet 8 1994 221-227
6. Koide R. Ikeuchi T. Onodera O. et al. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA) Nat Genet 6 1994 9-13
7. Nagafuchi S. Yanagisawa H. Sato K. et al. Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p Nat Genet 6 1994 14-18
8. Sieradzan K.A. Mann D.M. The selective vulnerability of nerve cells in Huntington's disease Neuropathol Appl Neurobiol 27 2001 1-21
9. Orr H.T. Beyond the Qs in the polyglutamine diseases Genes Dev 15 2001 925-932
10. Fischbeck K.H. Polyglutamine expansion neurodegenerative disease Brain Res Bull 56 2001 161-163
11. DiFiglia M. Sapp E. Chase K.O. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 277 1997 1990-1993
12. Becher M.W. Kotzuk J.A. Sharp A.H. et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length Neurobiol Dis 4 1998 387-397
13. Gutekunst C.A. Li S.H. Yi H. et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology J Neurosci 19 1999 2522-2534
14. Davies S.W. Turmaine M. Cozens B.A. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation Cell 90 1997 537-548
15. Lunkes A. Mandel J.L. A cellular model that recapitulates major pathogenic steps of Huntington's disease Hum Mol Genet 7 1998 1355-1361
16. Sieradzan K.A. Mechan A.O. Jones L. Wanker E.E. Nukina N. Mann D.M. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein Exp Neurol 156 1999 92-99
17. Hodgson J.G. Agopyan N. Gutekunst C.A. et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration Neuron 23 1999 181-192
18. Wellington C.L. Ellerby L.M. Hackam A.S. et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract J Biol Chem 273 1998 9158-9167
19. Wellington C.L. Ellerby L.M. Gutekunst C.A. et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease J Neurosci 22 2002 7862-7872
20. Andrade M.A. Bork P. HEAT repeats in the Huntington's disease protein Nat Genet 1995 115-116
21. Singaraja R.R. Hadano S. Metzler M. et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis Hum Mol Genet 11 2002 2815-2828
22. Henry K.R. D'Hondt K. Chang J. et al. Scd5p and clathrin function are important for cortical actin organization, endocytosis, and localization of sla2p in yeast Mol Biol Cell 13 2002 2607-2625
23. McCampbell A. Taylor J.P. Taye A.A. et al. CREB-binding protein sequestration by expanded polyglutamine Hum Mol Genet 9 2000 2197-2202
24. Nucifora F.C.Jr. Sasaki M. Peters M.F. et al. Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity Science 291 2001 2423-2428
25. Ross C.A. When more is less: pathogenesis of glutamine repeat neurodegenerative diseases Neuron 15 1995 493-496
26. Sharp A.H. Loev S.J. Schilling G. et al. Widespread expression of the Huntington's disease gene (IT-15) protein product Neuron 14 1995 1065-1074
27. Landwehrmeyer G.B. McNeil S.M. Dure L.S. IV et al. Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals Ann Neurol 37 1995 218-230
28. Bhide P.G. Day M. Sapp E. et al. Expression of normal and mutant huntingtin in the developing brain J Neurosci 16 1996 5523-5535
29. Fusco F.R. Chen Q. Lamoreaux W.J. et al. Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease J Neurosci 19 1999 1189-1202
30. Perutz M. Polar zippers: their role in human disease Protein Sci 3 1994 1629-1637
31. Scherzinger E. Lurz R. Turmaine M. et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo Cell 90 1997 549-558
32. Scherzinger E. Sittler A. Schweiger K. et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology Proc Natl Acad Sci USA 96 1999 4604-4609
33. Li S.H. Cheng A.L. Zhou H. et al. Interaction of Huntington disease protein with transcriptional activator Sp1 Mol Cell Biol 22 2002 1277-1287
34. Dunah A.W. Jeong H. Griffin A. et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease Science 296 2002 2238-2243
35. Roon-Mom W.M. Reid S.J. Jones A.L. MacDonald M.E. Faull R.L. Snell R.G. Insoluble TATA-binding protein accumulation in Huntington's disease cortex Brain Res Mol Brain Res 109 2002 1-10
36. ll130, interfering with CREB-dependent transcription Nat Genet 26 2000 29-35
37. Poirier M.A. Li H. Macosko J. Cai S. Amzel M. Ross C.A. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization J Biol Chem 277 2002 41032-41037
38. Bence N.F. Sampat R.M. Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation Science 292 2001 1552-1555
39. Cummings C.J. Mancini M.A. Antalffy B. DeFranco D.B. Orr H.T. Zoghbi H.Y. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1 Nat Genet 19 1998 148-154
40. Jana N.R. Tanaka M. Wang G. Nukina N. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity Hum Mol Genet 9 2000 2009-2018
41. Wyttenbach A. Sauvageot O. Carmichael J. Diaz-Latoud C. Arrigo A.P. Rubinsztein D.C. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin Hum Mol Genet 11 2002 1137-1151
42. Reddy P.H. Williams M. Charles V. et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA Nat Genet 20 1998 198-202
43. Lin C.H. Tallaksen-Greene S. Chien W.M. et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease Hum Mol Genet 10 2001 137-144
44. Levine M.S. Klapstein G.J. Koppel A. et al. Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease J Neurosci Res 58 1999 515-532
45. Q111 knock-in mice Hum Mol Genet 9 2000 503-513
46. Mangiarini L. Sathasivam K. Seller M. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice Cell 87 1996 493-506
47. Yamamoto A. Lucas J.J. Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease Cell 101 2000 57-66
48. Schilling G. Becher M.W. Sharp A.H. et al. Intranuclear inclusions and neuritic pathology in transgenic mice expressing a mutant N-terminal fragment of huntingtin Hum Mol Genet 8 1999 397-407
49. Laforet G.A. Sapp E. Chase K. et al. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease J Neurosci 21 2001 9112-9123
50. Shelbourne P.F. Killeen N. Hevner R.F. et al. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice Hum Mol Genet 8 1999 763-774
51. Watase K. Weeber E.J. Xu B. et al A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration Neuron 34 2002 905-919
52. Turmaine M. Raza A. Mahal A. Mangiarini L. Bates G.P. Davies S.W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease Proc Natl Acad Sci USA 97 2000 8093-8097
53. Yu Z.X. Li S.H. Evans J. Pillarisetti A. Li H. Li X.J. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease J Neurosci 23 2003 2193-2202
54. Gurney M.E. Cuttings F.B. Zhai P. et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis Ann Neurol 39 1996 147-157
55. Gurney ME, Cutting FB, Zhai P. Therapeutic benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis (FALS). In: Nakano I, Hirano A, editors. Amyotrophic lateral sclerosis, progress and perspectives in basic research and clinical application. Amsterdam; Elsevier, 1996. pp. 322-30.
56. Gurney M.E. Pu H. Chiu A.Y. et al Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation Science 264 1994 1772-1775
57. Wong P.C. Pardo C.A. Borchelt D.R. et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria Neuron 14 1995 1105-1116
58. Price D.L. Sisodia S.S. Borchelt D.R. Genetic neurodegenerative diseases: the human illness and transgenic models Science 282 1998 1079-1083
59. Schilling G. Coonfield M.L. Ross C.A. Borchelt D.R. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model Neurosci Lett 315 2001 149-153
60. Hockly E. Richon V.M. Woodman B. et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease Proc Natl Acad Sci USA 100 2003 2041-2046
61. Steffan J.S. Bodai L. Pallos J. et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila Nature 413 2001 739-743
62. McCampbell A. Taye A.A. Whitty L. Penney E. Steffan J.S. Fischbeck K.H. Histone deacetylase inhibitors reduce polyglutamine toxicity Proc Natl Acad Sci USA 98 2001 15179-15184
63. de Almeida L.P. Ross C.A. Zala D. Aebischer P. Deglon N. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length J Neurosci 22 2002 3473-3483
64. Browne S.E. Bowling A.C. MacGarvey U. et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia Ann Neurol 41 1997 646-653
65. Beal M.F. Mitochondrial dysfunction in neurodegenerative diseases Biochim Biophys Acta 1366 1998 211-223
66. Matthews R.T. Yang L. Browne W. Baik M. Beal M.F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective efforts Proc Natl Acad Sci USA 95 1998 8892-8897
67. Cramer C.L. Stagnitto M.L. Knowles M.A. Palmer G.C. Kainic acid and 4-aminopyridine seizure models in mice: evaluation of efficacy of anti-epileptic agents and calcium antagonists Life Sci 54 1994 L271-L275
68. The Huntington's Study Group A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease Neurology 57 2001 397-404
69. Ferrante R.J. Andreassen O.A. Dedeoglu A. et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease J Neurosci 22 2002 1592-1599
70. Ferrante R.J. Andreassen O.A. Jenkins B.G. et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease J Neurosci 20 2000 4389-4397
71. Andreassen O.A. Dedeoglu A. Ferrante R.J. et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease Neurobiol Dis 8 2001 479-491
72. Andreassen O.A. Ferrante R.J. Huang H.M. et al. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease Ann Neurol 50 2001 112-117
73. Ona V.O. Li M. Vonsattel J.P. et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease Nature 399 1999 263-267
74. Chen M. Ona V.O. Li M. et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease Nat Med 6 2000 797-801
75. Andreassen O.A. Ferrante R.J. Dedeoglu A. Beal M.F. Lipoic acid improves survival in transgenic mouse models of Huntington's disease NeuroReport 12 2001 3371-3373
76. Smith D.L. Portier R. Woodman B. et al. Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles Neurobiol Dis 8 2001 1017-1026
77. Nagai Y. Tucker T. Ren H. et al. Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening J Biol Chem 275 2000 10437-10442
78. Ren H. Nagai Y. Tucker T. Strittmatter W.J. Burke J.R. Amino acid sequence requirements of peptides that inhibit polyglutamine-protein aggregation and cell death Biochem Biophys Res Commun 288 2001 703-710
79. Kazantsev A. Walker H.A. Slepko N. et al. A bivalent huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila Nat Genet 30 2002 367-376
80. Thakur A.K. Wetzel R. Mutational analysis of the structural organization of polyglutamine aggregates Proc Natl Acad Sci USA 99 2002 17014-17019
81. Dedeoglu A. Kubilus J.K. Jeitner T.M. et al. Therapeutic effects of cystamine in a murine model of Huntington's disease J Neurosci 22 2002 8942-8950
82. Luthi-Carter R. Strand A. Peters N.L. et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease Hum Mol Genet 9 2000 1259-1271
83. Luthi-Carter R. Strand A.D. Hanson S.A. et al. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects Hum Mol Genet 11 2002 1927-1937